Please provide your email address to receive an email when new articles are posted on . Idorsia Pharmaceuticals announced that a citizen petition was filed on its behalf, asking the DEA to de-schedule ...

Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult ...

Idorsia is a Swiss biopharmaceutical company with multiple commercial and pre-commercial assets. Idorisa's lead asset Daridorexant seems to be a more attractive option compared to SOC in Isomnia due ...

NDA includes robust data from a Phase 3 trial that demonstrated efficacy of daridorexant on improving Total Sleep Time and Latency for Sleep Onset, while maintaining a favorable safety profile Sosei ...